The bone marrow-derived endothelial progenitor cell response is impaired in delayed wound healing from ischemia  by Bauer, Stephen M. et al.
The bone marrow-derived endothelial progenitor
cell response is impaired in delayed wound healing
from ischemia
Stephen M. Bauer, MD, Lee J. Goldstein, MD, Richard J. Bauer, PhD, Haiying Chen, MD, Mary Putt,
ScD, PhD, and Omaida C. Velazquez, MD, Philadelphia, Penn
Objective:Vasculogenesis relies on the recruitment of bone marrow-derived endothelial progenitor cells (BMDEPCs) and
is stimulated by tissue-level ischemia. We hypothesized that the BMD EPC response is impaired in ischemic wounds and
studied the relationship between BMD EPCs and wound healing.
Methods: We used transgenic Tie-2/LacZ mice, which carry the -galactosidase (-gal) reporter gene under Tie-2
promoter control. Wild-type mice were lethally irradiated and reconstituted with Tie-2/LacZ bone marrow. Four weeks
later, the mice underwent unilateral femoral artery ligation/excision and bilateral wounding of the hindlimbs. Ischemia
was confirmed and monitored with laser Doppler imaging. A subset of mice received incisional vs excisional nonischemic
bilateral hindlimb wounds, without femoral ligation. Excisional wound closure was measured by using daily digital
imaging and software-assisted calculation of surface area.
Results: Ischemia resulted in significantly delayed wound healing and differentially affected the number of BMD EPCs
recruited to wound granulation tissue and muscle underlying the wounds. At 3 days postwounding, the granulation
tissue of the wound base contained significantly fewer numbers of BMD EPCs in ischemic wounds compared with the
nonischemic wounds (P < .05). In contrast, significantly more BMD EPCs were present in the muscle underlying the
ischemic wounds at this same time point compared with the muscle under the nonischemic wounds (P< .05). In ischemic
wounds, eventual wound closure significantly correlated with a delayed rise in BMD EPCs within the wound granulation
tissue (Kendall’s correlation, –.811, P  .0005) and was significantly associated with a gradual recovery of hindlimb
perfusion (P < .0001). By 7 days postwounding, BMD EPCs were incorporated into the neovessels in the granulation
tissue. At 14 days and 75 days, BMD EPCs were rarely observed within the wounds.
Conclusions:Granulation tissue of excisional ischemic wounds showed significantly less BMDEPCs 3 days postwounding,
in association with significantly delayed wound closure. However, the number of BMD EPCs were increased in ischemic
hindlimb skeletal muscle, consistent with the notion that ischemia is a powerful signal for vasculogenesis. To our
knowledge, this is the first report identifying a deficit in BMDEPCs in the granulation tissue of ischemic skin wounds and
reporting the key role for these cells in both ischemic and nonischemic wound healing. (J Vasc Surg 2006;43:134-41.)
Clinical Relevance: The reported novel findings offer new insight into the pathophysiology of nonhealing ischemic skin
ulcers and point to a potential new target for therapeutic intervention. Further work in this area is needed to better
understand the local biology and cytokine milieu of the local environment in the ischemic wound. Ultimately, approaches
such as repopulating the local wound pool of bone-marrow derived endothelial progenitor cells (BMD EPCs) in ischemic
wounds through direct injection or increasing stimulatory cytokines within the wound’s granulation tissue that may
increase recruitment of BMD EPCs (or decreasing cytokines inhibitory of this process) may have potential therapeutic
benefit. Currently the only way to salvage an ischemic limb with tissue loss is to restore blood flow with bypass surgery
or, at times, balloon angioplasty and stenting. These are invasive procedures that often fail to salvage the limb because of
poor skin-level tissue perfusion. Thus far, few clinical trials have looked at BMD EPCs as a therapeutic option. A better
understanding of the biology of BMD EPCs and their role in ischemic wound healing is paramount before a strong
rationale can be built for successful therapeutic interventions.Ischemic wounds are costly, debilitating, and often lead
to limb amputations, infections, and increased mortality.1
Although multiple factors contribute to their pathogenesis,
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134one significant impairment is deficient tissue-level neovas-
cularization.2 Neovascularization is essential for wound
healing because it replaces damaged capillaries and re-
establishes the supply of oxygen and nutrients. The main-
stay treatments for chronic ischemic wounds are revascular-
ization procedures and local wound care regimens. Despite
the numerous advances in endovascular procedures, surgi-
cal bypass approaches, and wound-healing research, isch-
emic nonhealing wounds continue to be a considerable
clinical challenge, with impaired tissue-level neovascular-
ization, and remain a serious unsolved problem.3
Postnatal neovascularization, both physiologic and
pathologic, relies on the two processes of angiogenesis and
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endothelial cells, derived from pre-existing blood vessels,
propagate new capillaries through migration, proliferation,
and morphologic differentiation.7,8 Vasculogenesis is the
de novo formation of immature cords through migration,
invasion, proliferation, and differentiation of endothelial
progenitor cells (EPCs) that subsequently undergo tubu-
logenesis and mature into capillaries, arterioles, arteries,
venules, and veins.6,9,10
In postnatal vasculogenesis, EPCs are believed to arise
from a population of progenitor cells in the bone marrow
that are positive for certain cell surface markers, such as
CD133, CD34, and low concentrations of vascular endo-
thelial growth factor receptor-2 (VEGFR-2).11 These pro-
genitor cells are indistinguishable from hematopoietic stem
cells until they commit to differentiating along the endo-
thelial lineage, where they gain specific endothelial cell
markers, such as Tie-2, high-level expression of VEGFR-2,
and von Willebrand factor (vWF).11-13 In unstressed con-
ditions, an estimated 0.002% of the circulating mononu-
clear cell fraction of whole blood are EPCs derived from the
bone marrow.5,14-16
After trauma or in tissue-level ischemia, elevated sys-
temic concentrations of vascular endothelial growth fac-
tor-A (VEGF-A) cause more EPCs to be released from the
bone marrow into peripheral circulation, where they then
follow cytokine gradients to sites of neovascularization.3 At
the needed tissue-level site, the bonemarrow-derived EPCs
(BMD EPCs) exit the circulation, invade or migrate
through the extracellular matrix, and contribute to neovas-
cularization by either direct vasculogenesis or by paracrine
mechanisms.11,13-15,17-20
Increasing the systemic EPC supply to ischemic tissues
is believed to have potential therapeutic benefit. For in-
stance, systemic injection of human BMD EPCs increases
capillary density and increases limb salvage in a murine
ischemic hindlimb model.11,17,21 Moreover, increasing the
local supply of BMD EPCs in human ischemic limbs im-
proved ankle-brachial index, pain-free walking time, rest
pain, and transcutaneous oxygen pressure.22 Likewise, re-
cent evidence also suggests that BMD EPCs are important
for vascular regeneration and wound healing.13,23-25 Tis-
sue ischemia is believed to be the strongest stimulus for
initiating vasculogenesis.11-13 However, ischemic skin-
level lower-extremity wounds demonstrate severely delayed
healing, both clinically and in experimental models, sug-
gesting that the EPC response in skin-level ischemia may be
incomplete or deficient.
We therefore tested the hypothesis that a decrease in
EPC recruitment in ischemic wounds potentially explains
the severe healing deficit that is observed clinically. We used
a transgenic Tie-2-LacZ murine model for our studies.
Expressed in all cells destined to differentiate along the
endothelial lineage (ie, all EPCs), Tie-2 binds the ligand
angiopoietin I and is a receptor specific to only endothelial
cells. Because Tie-2 continues to be expressed in mature
endothelial cells, Tie-2-LacZ transgenic mice, which have
the Tie-2 promoter linked to a -galactosidase reportergene LacZ, not only express Tie-2 on EPCs but also on
endothelial cells of peripheral tissues. Therefore, a bone
marrow transplantation model using transgenic bone mar-
row and wild-type recipients is required to track bone
marrow-derived EPCs because of their Tie-2-LacZ trans-
genic label.
METHODS
Bone marrow transplantation model. The Univer-
sity of Pennsylvania Institutional Animal Care and Use
Committee approved all protocols. For all procedures, mice
were anesthetized with 0.5 mL titrated inhaled methoxy-
flurane (Vedco Inc, St. Joseph, Mo) and an intraperitoneal
injection of 100 mg/mL ketamine (Ketaject, Phoenix Sci-
entific, Inc, St. Joseph, Mo) and xylazine (TranquiVed,
Vedco Inc).
Chimeric mice were formed using bone marrow from
FVB/Tie-2/LacZ transgenic mice (FVB/N-
TgN[TIE2LacZ]182Sato, The Jackson Laboratory, Bar
Harbor, Me), which allowed us to track bone marrow-
derived Tie-2-expressing cells by virtue of their -gal ex-
pression. FVB wild-type mice (FVB/NJ, The Jackson Lab-
oratory), 8 to 14 weeks old, underwent bone marrow
ablation by lethal irradiation with 900 rad (fractionated
into two doses of 450 rad, 24 hours apart) (Shepard Mark
IV Irradiator kindly provided by Cameron Koch PhD, the
University of Pennsylvania).
Twenty-four hours after bone marrow ablation, the
recipient mice underwent rescue bone marrow transplanta-
tion with the mononuclear cell fraction of bone marrow
flushed from the femurs of two syngeneic Tie-2/LacZ
donor mice (5 million cells in 300 L 1 ice-cold phos-
phate-buffered saline [PBS], injected intravenously by tail
vein). Four weeks were then allowed for engraftment.
Chimeric mice were confirmed by detecting the LacZ gene
with polymerase chain reaction (PCR).
Ischemic wound-healing model. Chimeric mice
were anesthetized as described, and a unilateral femoral
artery and vein ligation/excision was performed. The ves-
sels were approached via a 4- to 5-mm ventral incision over
the proximal hindlimb. The artery and vein were dissected
free from the femoral nerve. The vessels were ligated prox-
imally and distally above the saphenous artery with 6-0
Ethibond braided suture (Ethicon, Somerville, NJ) and a
2-mm segment was excised (ligation of both artery and vein
en bloc is technically simple and avoids venous tears and
undue bleeding from separating these two diminutive mu-
rine vessels). The incision was closed with interrupted 5-0
Nylon suture (Ethicon).
Next, the mice received bilateral excisional wounds
with a 3-mm punch biopsy on the ventral hindlimb distal to
the ligation. Additional control mice underwent incisional
vs excisional nonischemic wounding. Specifically, chimeric
mice underwent a unilateral 3-mm punch biopsy wound
and received a contralateral 3-mm incision that was then
closed primarily. No femoral vessels were ligated in this
subset of mice.
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Wilmington, Del) and LDI software-calculated perfusion
(expressed as a measure of flux) of the hindlimbs were
performed to confirm and monitor ischemia.26 In the laser
Doppler blood flow imager, a low-intensity laser beam
(633 nm) is scanned across a tissue surface. Blood flow
measurements of the microvasculature are calculated with a
256 256 pixel resolution, with each pixel being an actual
measurement of flux or blood flow (speed of blood cells 
blood volume).26 LDI assessments were obtained preoper-
atively, immediately postoperatively, and every other day.
Digital photographs of the wounds with an internal scale
were obtained and wound surface areas were calculated
using Image J software-assisted calculations (Imaging Pro-
cessing and Analysis in Java, National Institutes of Health).
Wound closure was calculated as percent of original wound
size.
Mice were sacrificed on postoperative days 1, 3, 7, 14,
and 75 (n  3 for days 1 and 75; n  5 on days 3, 7, and
14). At the time of initial operation (0 day), excisional
wound skin was analyzed for baseline BMD EPC counts.
Although some wounds completely healed, the area of scar
was easily detected after removing hair with depilatory
cream.
To control for potential systemic signals in response to
limb ischemia (which would influence the EPC recruitment
to the contralateral nonischemic wound), six mice were also
studied where a unilateral excisional wound was performed
with a contralateral incisional wound and no femoral vessel
ligation. The excisional punch biopsy wounds, incisional
control wounds, muscle underlying wounds, skin adjacent
to the wounds, and remote uninjured skin from the abdo-
menwere harvested. In addition, excisional wound skin was
analyzed at the time of the initial operation (0 day) for
baseline BMD EPC counts.
Confirmation of chimerism. Chimerism was con-
firmed with PCR for the LacZ gene by using The Jackson
Laboratory’s genotyping protocol. At the time of wound
harvest, DNA was isolated from bone marrow cells using
Qiagen’s DNeasy Tissue Kit (Valencia, Calif). A 315-bp
stretch of the LacZ gene was amplified using 5=-ATC-
CTCTGCATGCTCAGGTC-3= and 3=-CGTGGCCT-
GATTCATTCC-5= at 94oC for 3 minutes; 12 cycles of
denaturation at 94oC for 30 seconds, annealing at 64oC for
30 seconds, and extension at 72oC for 30 seconds. This was
followed by 25 cycles of denaturation at 94oC for 30
seconds, annealing at 58oC for 30 seconds, extension at
72oC for 30 seconds, and a final elongation step at 72oC for
2 minutes.
-Galactosidase assay. Bone marrow-derived EPCs
were quantified using a -gal assay. Tissues were fixed for
10 minutes in 0.5% glutaraldehyde and then washed twice
with PBS/magnesium chloride solution (10 minutes each
wash). The tissues were then incubated with X-gal solution
at 37oC overnight, fixed in Prefer solution (Anatech Ltd,
Battle Creek, Mi) or 2 hours, and then embedded in
paraffin. Paraffin-embedded serial sections were deparaf-
finized, rehydrated, and counterstained with nuclear fastred. BMD EPC numbers were quantified by counting
-gal cells at early and late time points in serial sections of
wound granulation tissue, skeletal muscle underlying the
excisional wounds, unwounded adjacent skin, incisional
wounds, and remote skin. Duplicate serial sections were
double stained for -gal and VEGFR-2, and -gal and
vWF.
Antibodies and reagents. Rabbit polyclonal anti-
mouse Flk-1 (VEGFR-2) antibodies were obtained from
Abcam (Cambridge, Mass); rabbit polyclonal antihuman
vWF antibodies (cross-reactive with murine vWF) were
purchased from DakoCytomation Inc, (Carpinteria, Calif).
Goat biotinylated antirabbit immunoglobulin G (IgG) was
obtained from Vector Laboratories, Inc (Burlingame, Cal-
if); Biostain Super ABC/Peroxidase/Mouse/Rat IgG Im-
munoassay Detection Kit was purchased from Biomeda
Corporation (Foster City, Calif); and Immunopure Metal
Enhanced DAB Substrate Kit was obtained from Pierce
(Rockford, Ill).
Immunohistochemistry. Immunohistochemistry was
performed on serial sections of paraffin-embedded tissue pre-
viously stained for-gal. Standardmethods of deparaffinizing,
rehydrating, and blocking followed by incubation with pri-
mary and secondary antibodies/reagents were used.27 All
experiments included negative-control stains in which no
primary antibody or an irrelevant primary antibody was used.
In vitro characterization of Tie-2-LacZ BMD EPCs was per-
formed as previously described.6,28,29 Paraffin-embedded sec-
tions from harvested wounds were double-stained for
VEGFR-2 and -gal, and vWF and –gal to confirm the
co-localization of endothelial lineage markers.
Statistical analysis. All experiments were indepen-
dently repeated at least three times. Quantification was
performed in at least 10 random40 high-power fields. All
data are presented as means  standard error of the mean
(SEM). Results from three individual experiments were
pooled for the analysis.
Differences between wound size in ischemic and non-
ischemic wounds over time were analyzed by using a series
of mixed-effects models that took into account the corre-
lation between the paired wounds on the two legs of an
individual animal as well as the correlations between the
size of an individual wound measured over time.30 With
this approach, we used likelihood ratio tests to determine
whether there was an effect of time on wound size, an effect
of wound type (ischemic vs nonischemic), and an effect of
wound type that varied over time. The mixed effects model
was used to estimate the mean difference and the 95%
confidence interval (CI) between ischemic and nonisch-
emic groups. We also used mixed-effects models to exam-
ine the differences between laser Doppler flow in the paired
legs of the individual animals and to examine the associa-
tion between wound size and flow in ischemic and nonisch-
emic wounds.
The laser flux data were log-transformed before analy-
sis. A likelihood ratio test was used to determine whether
there were differences in the relationship between flow and
wound size for the ischemic and nonischemic groups, and
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association between wound size and laser flow for each
group. Estimates of flow rates and 95% CI for the two
groups for a wound size of 100% and 0% were then con-
structed from the mixed-effects model.
The correlation between wound size, normalized to an
initial wound size of 100%, and EPC concentrations were
assessed using Kendall’s tau, a method that accounts for
possible non-normality in the data;31 t tests were used for
the comparison of continuous data. We used R-2.1 (2005)
to fit the mixed effects model and perform Kendall’s tau,
and Excel (Microsoft, Redmond, Wash) to carry out the t
tests. The type I error rate for all tests was 0.05 and all tests
were two-sided.
RESULTS
Significant relationship between hindlimb ischemia
and wound healing. Femoral ligation/excision consis-
tently significantly decreased limb perfusion, measured by
LDI flux assessment, in the ischemic hindlimb compared
with the contralateral nonischemic hindlimb (P  .005)
(Fig 1, A to C). Ischemic excisional wounds also demon-
strated significantly delayed closure compared with non-
ischemic wounds, especially on days 2 through 6, where
there was nearly a threefold difference in the percent of
wound closure from the original wound size (P  .05) (Fig
Fig 1. In our murine in vivo model, femoral ligation/excision
results in significant hindlimb ischemia and delayed wound heal-
ing. A, Preoperative laser Doppler imaging (LDI) demonstrates
good perfusion down each hindlimb. B, Postoperative LDI dem-
onstrates decreased perfusion in the hindlimb ipsilateral to the
femoral ligation (arrow). C, Software-calculated average hindlimb
flux (index of perfusion) by LDI; the hindlimb ipsilateral to the
femoral ligation (ischemic) is shown in grey, and the hindlimb
contralateral to the femoral ligation (nonischemic) is shown in
black. Data are expressed as mean  SEM. D, Representative
mouse at postoperative day 5 and (E)day 7 demonstrates delayed
healing of hindlimb excisional wounds on the ischemic hindlimbs
(blue arrow) compared with the acutely healing wounds on the
nonischemic hindlimb (red arrow). F, Wound closure rates are
expressed as percent of original wound’s surface area (SA). Data
are expressed as mean SEM; *P .005 ischemic vs nonischemic.1, D to F). All ischemic wounds eventually healed, becausein our murine hindlimb ischemia model, the animals spon-
taneously recovered a significant degree of hindlimb perfu-
sion after 8 to 10 days following femoral ligation/excision
as determined by LDI flux (data not shown).
Although wound size decreased over time (P .0001),
the mean difference in size between nonischemic and isch-
emic wounds was 32.1% (95% CI, 19.7% to 44.5%; P 
.0001), with no statistically significant differential changes
over time (P .3325). We found the association of wound
size with flow was significantly different for ischemic and
nonischemic animals (P  .0003). In the non-ischemic
group, there was no statistical association between wound
size and flow (P  .1229); but in the ischemic group,
decreasing wound size was associated with increasing flow
(P  .0001).
Significant relationship between wound healing
and the BMD EPC response. At 3 days postwounding,
ischemic wounds showed a significant delay in closure
(Fig 1, F ), and we observed approximately threefold less
BMD EPCs in ischemic wounds than nonischemic
wounds (Fig 2, A and B, G), (P  .005). Within the first
3 days, all acutely healing excisional punch biopsy
wounds showed abundant numbers of BMD EPCs that
initially formed clusters of round, undifferentiated,
-gal cells and subsequently incorporated into the
blood vessel walls by 7 days.
The BMD EPC response within granulation tissue of
excisional wounds was also significantly impaired in isch-
emic delayed-healing wounds compared with nonisch-
emic wounds at 3 days, but was similar by 7 days after
wounding (more details in Fig 3). This increase in BMD
EPCs for ischemic wounds was associated with the
wound closure that we observed from 7 days and be-
yond. These findings were statistically significant; where
wound size and EPC numbers were very negatively
correlated with smaller, faster-healing wounds recruiting
higher numbers of BMD EPCs (Kendall’s correlation,
–.811; P  .0005).
Differential BMD EPC response in ischemic gran-
ulation tissue vs muscle and excisional vs incisional
wounds. Unlike the significantly less BMD EPCs seen in
ischemic granulation tissues, we observed significantly
more BMD EPCs in the ischemic vs nonischemic hindlimb
muscles underlying the excisional punch biopsy wounds
(Fig 2, C and D, G) (P  .005). This is consistent with the
notion that tissue-level ischemia is essential for vasculogen-
esis at the muscle level, not at the granulation tissue level.
Excisional wounds showed a stronger vasculogenic
stimulus than incisional wounds (Fig 2, E and F, G). Chi-
meric mice, without femoral ligation, which received a
nonischemic hindlimb excisional and contralateral inci-
sional wound, had significantly more BMD EPC in exci-
sional wounds at 3 days postwounding compared with
incisional wounds (Fig 2, E and F, G), (P  .0001).
However, these excisional wounds contained statistically
significant less BMD EPCs than equivalent nonischemic
excisional wounds in the presence of contralateral hindlimb
ischemia (P  .05), (Fig 2, G).
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BMD EPC response observed at 3 days quickly subsided in
all tissues examined, particularly after 7 days postwounding
(Figs 3 and 4). Fewer clusters of BMD EPCs were ob-
served, but a significant number of BMD EPCs incorpo-
rated into the wound neovasculature at 7 days postwound-
ing in both nonischemic and ischemic wounds (Fig 3 and
4).
At 3 days, BMD EPCs were rarely localized to the
Fig 2. Bone marrow-derived endothelial progenitor cells (BMD
EPCs) within tissues at 3 days postwounding. Representative
biopsy specimens focusing on the wound base in (A) nonischemic
and (B) ischemic granulation tissue (40) in mice that underwent
unilateral femoral ligation/excision and bilateral hindlimb punch
biopsy, Inserts show low-power (4) view of entire harvested
tissue with wound surface oriented towards the right side; BMD
EPCs are identified as -galactosidase cells (blue). C, Non-
ischemic and (D) ischemic skeletal muscle underlying wounds
shown above in A and B (40). Representative wound biopsy
specimens of (E) incisional and (F) excisional wounds in mice
without femoral ligation. G, Data show mean  SEM of BMD
EPC counts in the nonischemic tissue (solid black), compared with
the ischemic tissue (solid grey), in mice that received a femoral
artery ligation; and in excisional compared with incisional wounds
in mice without femoral ligation (thatched).*P .005 ischemic vs
non-ischemic tissue; †P .05 thatched vs solid black nonischemic
excisional wounds; **P  .05 in incisional vs excisional without
femoral ligation.vessel walls within the neovasculature but instead werefound in the extra-cellular matrix, either as single migrating
cells or forming cell clusters. At 7 days, EPCs incorporated
into the neovasculature, forming part of the vessel walls.
Approximately 20% of the total BMDEPCs counted within
the wound granulation tissue at 7 days were physically
incorporated into the vessel walls.
Moreover, by 7 days postwounding, nonischemic exci-
sional wounds completely closed when measured by soft-
ware-assisted surface area calculations. Further histologic
confirmation demonstrated re-epithelialization of the
wound surface (Fig 4, A), whereas the ischemic excisional
wounds continued to show significant delayed healing (Fig
4, C), yet the number of BMD EPCs in the ischemic
wounds begin to closely correspond to the amount found
in nonischemic wounds (Fig 3). Furthermore, at this 7-day
time point, the acute BMD EPC response observed at 3
days postwounding in nonischemic granulation tissue of
excisional wounds subsides. Specifically, we observed less
BMD EPCs in the extracellular matrix, but some BMD
EPCs incorporated into the neovasculature in both isch-
emic and nonischemic excisional wounds (Fig 4, B and D).
Even more so, BMD EPC were present within the
tissues at all time points examined (extracellular matrix and
vessels), shown by the co-localization of -gal expression
with either VEGFR-2 and vWF expression (Fig 5), indicat-
ing that as these cells migrate into the healing tissue, they
already express mature endothelial cells markers.
Ischemia spontaneously resolves and wounds heal
by day 14. In our wound-healing model, all excisional
skin wounds fully healed with a complete layer of keratin-
ized squamous epithelium, collagen formation, and mature
neovasculature by 14 days postwounding. Furthermore, all
ischemic hindlimbs spontaneously recovered LDI flux
(data not shown) and by this time we observed an average
of less than two BMD EPCs per high-power field in all
ischemic wounds and in all excisional wounds healing by
secondary intention (Fig 3). By 75 days postwounding,
except for rare outliers, BMD EPCs were neither found in
the extracellular matrix nor the neovasculature of the well-
Fig 3. Bone marrow-derived endothelial progenitor cells (BMD
EPCs) presence in tissues over time. Mean BMD EPC within (A)
wound granulation tissue in mice that underwent unilateral femo-
ral ligation and bilateral excisional punch biopsy wounds; (B)
skeletal muscle underlying the excisional wounds from mice in A;
(C) incisional and excisional wounds in mice without femoral
ligation. Data are mean  SEM. *P  0.05.healed skin wounds.
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showed new blood vessels and a return of skin appendages
in both the nonischemic and initially ischemic hindlimbs.
Muscle from the nonischemic hindlimb had normal histo-
logic architecture at early and late time points. Interest-
ingly, the muscle from the initially ischemic hindlimbs,
which at earlier time points showed areas of necrosis and
had a strong BMDEPC response, by 75 days demonstrated
a complete restoration of normal histologic architecture
with refilling of the femoral artery and vein from collateral
circulation. As observed at the skin level, with rare excep-
tions, BMD EPCs were no longer present or seen in the
neovasculature walls of the healed muscle.
DISCUSSION
In this study, we report that acute healing for nonisch-
emic excisional wounds correlates with BMD EPC pres-
Fig 4. Bone marrow-derived endothelial progenitor cells (BMD
EPCs) become incorporated into the neovasculature at post-
wounding day 7. A, Representative nonischemic wound at 7 days
after wounding shows complete skin healing with the original
wound covered by keratinized squamous epithelium. B, The un-
derlying tissue in the wound depicted in A demonstrates good
vascularity and fibrosis, with a paucity of BMD EPCs in the
extracellular matrix and with several BMDEPCs incorporated into
the wall of blood vessels (one vessel shownmagnified within insert.
Insert: -galactosidase endothelial cells lining a blood vessel
(arrow), representing fully differentiated BMDEPCs incorporated
into the neovasculature at 7 days. C, Representative ischemic
wound that histologically still has a gap in the regenerating epithe-
lium at 7 days after wounding, consistent with the gross appear-
ance of delayed healing in these ischemic wounds. D, The under-
lying tissue of the wound depicted in C has an appearance
consistent with granulation tissue containing immature capillaries,
high cellularity, and the beginning of fibroplasia. Insert: magnified
area from D shows mature endothelial cells of BMD EPC origin
(-galactosidase) incorporated into the neovasculature of the
ischemic wound (arrow). Some BMDEPCs (-galactosidase cells
stained in blue) are pointed out by black arrows in panels B and D.ence, the key cellular effectors of postnatal vasculogenesis.We further show that ischemic wound granulation tissue
suffers from a significant impairment in BMD EPC recruit-
ment and delayed healing. At 3 days postwounding, nearly
threefold more BMD EPCs were within ischemic granula-
tion tissue compared with nonischemic wounds.
Paradoxically, the underlying muscle had increased
BMD EPC recruitment compared with the nonischemic
hindlimb muscle, demonstrating that BMD EPCs are re-
cruited by the ischemic muscle stimulus but not by the
ischemic granulation tissue of the skin wound bed. Collec-
tively, this suggests that the paucity of BMD EPCs in
ischemic granulation tissue is likely not due to a hemody-
namic effect but instead is secondary to specific signaling
mechanisms, for example, the presence of inhibitory cyto-
kines or a decrease in stimulatory cytokines within the
excisional ischemic skin wound.32 Alternatively, the isch-
emic muscle may compete with the skin-level granulation
tissue during the recruitment of circulating BMD EPCs.
Bone marrow-derived EPCs clearly participated in vas-
culogenesis because our observed BMD EPC response was
strongly correlated with wound healing and the BMD
EPCs that incorporated into the neovasculature of the
healing wounds at 7 days expressed mature endothelial cell
surface markers. But our finding that substantially more
Fig 5. Co-localization of -gal/VEGFR-2 and -gal/vWF
stains on bone marrow-derived endothelial progenitor cells (BMD
EPCs) within extracellular matrix and within the walls of mature
blood vessels of granulation tissue. Representative cross-sections
from granulation tissue of acutely healing non-ischemic excisional
wounds at 3 days (A and B) and 7 days (C andD) postwounding.
A, -gal stain identifies BMD EPCs within extracellular matrix;
(B) these cells also stain positive for VEGFR-2. C, -Gal stain
identifies a blood vessel lined by BMD EPCs, see magnification in
outlined insert. D, The BMD EPCs in C also stain positive for
vWF. Inserts show blood vessel identified by arrow under 100
magnification. Arrowhead in C andD point to -gal BMD EPCs
lining blood vessel structure that is magnified within inserts. Black
arrows in B and in the D insert point to double-stained BMD
EPCs. -gal, -Galactosidase; VEGFR, vascular endothelial
growth factor receptor; vWF, von Willebrand factor.BMD EPCs were initially recruited to the wound than the
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the wound neovasculature suggests that the acute BMD
EPC response may contribute to wound healing by para-
crine mechanisms in addition to participating in vasculo-
genesis. The paucity of BMD EPCs at late time points may
coincide with ongoing remodeling of healing wounds and
the corresponding natural cellular turnover of skin.
Our data demonstrate the degree of injury and ischemia
affect on BMD EPC recruitment. Excisional wounds heal-
ing by secondary intention recruited more BMD EPCs
than incisional wounds healing by primary intention. Ad-
ditionally, ischemia induced by femoral artery ligation
caused a more pronounced recruitment of BMD EPCs to
the nonischemic contralateral excisional wound. This indi-
cates that an ischemic stimulus causes a more robust sys-
temic mobilization of BMD EPCs from the bone marrow,
which are then available to target the healing wound.
Bone marrow-derived EPCs likely undergo apoptosis
after participating in acute wound healing, although this
was not specifically addressed in this current work. BMD
EPCs are known to begin differentiating into endothelial
cells once in the peripheral circulation and completely
mature to endothelial cells as they incorporate into vessel
walls upon arriving to the tissue.3 It is unlikely that the
BMD EPCs found at 3 days postwounding undifferenti-
ated and migrated away by 7 days. Yet, future studies are
necessary and will surely expand our understanding of the
life cycle of these cells within various wound types.
Despite this, our data indeed suggest that BMD EPCs
indirectly participate in angiogenesis and wound healing,
via paracrine mechanisms, and directly participate in vascu-
logenesis by partially incorporating and forming new vessel
walls. So, too, are our findings consistent with other prior
vasculogenesis studies because we also observe that an
ischemic stimulus induced by femoral arterial ligation or
tissue injury likely initiates a vasculogenic cascade. Indeed,
we observed more BMD EPC in nonischemic granulation
tissue contralateral to the femoral ligation and in the ipsi-
lateral ischemic muscle.
It is also well documented that in response to either
ischemia or tissue trauma, local tissue VEGF-A release
initiates the vasculogenic cascade by increasing circulating
VEGF-A concentrations and subsequently increasing circu-
lating BMD EPCs.6,13,19,20 In the bone marrow, VEGF-A
activates matrix metalloproteinase-9, which releases soluble
Kit ligand (sKitL) by cleaving membrane Kit ligand. sKitL,
via its receptor (cKit), then activates BMD EPCs from their
quiescent state in the bone marrow, where they then mo-
bilize into circulation and target areas of needed neovascu-
larization.14,15 Recent evidence suggests that at the tissue
level, these vasculogenic signals are mediated by stromal
cell-derived factor-133 and -2 integrin.17 Our findings are
consistent with prior reports showing that BMD EPCs
migrate through extracellular matrix28(similar to mature
endothelial cells34) and express mature endothelial cell
markers.14,15,28,35
We also expand this knowledge by demonstrating that
tissues needing vasculogenesis cannot equally induce anacute BMD EPC response. Granulation tissues of ischemic
skin wounds, unlike excisional nonischemic wounds or
ischemic skeletal muscle, significantly suffer from an early
deficit of BMD EPCs. We currently identify a novel and
potential early factor that may convert acutely healing skin
wounds into chronic wounds.
Using an ischemic skin flap model, Tepper et al13
reported that BMD EPCs incorporated into the neovascu-
lature by 21 days after the initiation of ischemia.13 In slight
contrast, BMD EPCs are observed in our model by 7 days
postwounding as fully differentiated endothelial cells incor-
porated into vessel walls. Model-specific differences may
explain the slight differences in the timing of the vasculo-
genic cascade. The model discussed by Tepper et al used a
silicone sheet inserted under the dorsal skin that kept the
overlying skin intact without any open wounds. Because
the skin has less collaterals than a mouse’s hindlimb, the
induced ischemia is much more chronic. This ischemic skin
flap model also creates a gradual ischemic gradient across
the lifted skin flap.
In contrast, our model creates severe, abrupt ischemia
of the entire hindlimb and induces a significant full-thick-
ness skin defect that is allowed to remain open and heal by
secondary intention. As a result, the mice spontaneously
develop hindlimb collaterals that decrease the ischemic
stimulus within 8 to 10 days. In our model, after the
ischemic response subsides, the initial vasculogenic mech-
anism likely yields to dominant angiogenic mechanisms
that are necessary for maintaining adult mouse vascular
homeostasis.
CONCLUSION
Although consistent with prior studies in other patho-
logic conditions (eg, ischemic limb skeletal muscle, retinal
injury, and infracted myocardium),14,15,36 our current
study reports the novel contribution BMDEPCs to wound
healing and identifies that the granulation tissue of ischemic
hindlimb wounds suffers from an impaired acute EPC
response where the BMD EPC response and wound heal-
ing are significantly correlated.
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